ClinicalTrials.gg
TerminatedNCT00999193Updated Jan 7, 2025

Proximal Humeral Comminuted Fractures in the Elderly - PERCELE Trial

An interventional study of locking plate, ORIF and Hemiarthroplasty in Humeral Fracture, sponsored by University of Helsinki. Terminated at 1 site in Finland. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by University of Helsinki · Not applicable, Interventional, and Treatment

Why this study was terminated
Recruitment decline and research question getting outdated
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Fractures of the proximal humerus are common in elderly patients. The optimal treatment of comminuted, displaced fractures is subject to controversy, and the results of operative treatment have not been shown to be superior to conservative treatment. The aim of the study is to compare locking plate osteosynthesis versus treatment with fracture hemiarthroplasty versus conservative treatment in a randomised, controlled protocol. The results of treatment are measured at 6 weeks, 3 months, 6 months, 12 months and 24 months. Main outcome measures are Pain at rest and activity (NRSs) and functional assessment of the shoulder with Constant Score. Secondary outcome measures are Simple Shoulder test (SST), Disabilities of the Arm, Shoulder and Hand (DASH), quality of life assessment (15D), subjective patient satisfaction and costs. The study also has a cohort follow-up of the patiens who decline randomisation.

The recruitment target was 90 patients, but the study recruitment was stopped due to slow recruitment (too few patients presenting with eligibile injury to the hospital) at 60 patients in November 2019.

02

Conditions studied

  • Humeral Fracture

Keywords

  • Shoulder
  • Fracture
  • Locking Plate
  • Hemiarthroplasty
  • Conservative
  • Comminuted Proximal Humerus Fracture
03

In context

Humeral Fractures

178 studies on the registry are indexed under Humeral Fractures; 25 are open to participants now.

This study's enrollment of 60 is close to the median of 56 across 100 interventional studies indexed under Humeral Fractures.

Browse Humeral Fractures studies →

Lead sponsor

University of Helsinki is the lead sponsor of 132 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years and older
  • Acute trauma: 1. randomisation (op vs cons) within 7 days of injury.
  • 3- or 4-part fracture with >5mm dislocation of the anatomic neck.

    • AO classification C1-2 for non-luxation fractures
    • AO classification C3 for luxation fractures

Exclusion criteria

Exclusion Criteria:

  • Head Splitting fracture
  • Open fracture
  • Additional fractures in the shoulder region
  • Other injuries requiring surgical treatment
  • Clinically significant injury of the brachial plexus or vasculature
  • Pathological fracture associated with cancer
  • History of a fracture of the clavicle, scapula or humerus, or history of a very significant disease or trauma of the shoulder region (hemiparesis, tumour, osteomyelitis, grave arthrosis etc)
  • Rheumatoid Arthritis in the shoulder requiring active treatment
  • Reduced co-operation or incapability for independent living (dementia, mental illness, drug- or alcohol abuse etc)
  • unwillingness to accept some of the treatment options.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Conservative Treatment

    Other: Conservative treatment

  • Experimental
    ORIF w. locking plate, no luxation

    Procedure: locking plate, ORIF

  • Experimental
    Hemiarthroplasty, no luxation

    Procedure: Hemiarthroplasty

Interventions

  • Procedurelocking plate, ORIF

    Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.

  • ProcedureHemiarthroplasty

    Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.

  • OtherConservative treatment

    Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.

06

What researchers measure

Primary outcomes

  1. Pain at rest Numeric Rating Scale 0-10 (NRS)

    Time frame: 6 weeks, 3 mo, 6 mo, 1 year, 2 years

  2. Pain in active motion NRS

    Time frame: 6 weeks, 3 mo, 6 mo, 1 year, 2 years

  3. Constant Score

    Time frame: 3 mo, 6 mo, 1 year, 2 years

Secondary outcomes

  1. Simple Shoulder Test (SST)

    Time frame: 3 mo, 6 mo, 1 year, 2 years

  2. Disabilities of the Arm, Shoulder and Hand (DASH)

    Time frame: 3 mo, 6 mo, 1 year, 2 years

  3. Quality of life assessed with 15D

    Time frame: 6 weeks, 3 mo, 6 mo, 1 year, 2 years

  4. Subjective satisfaction

    Time frame: 6 weeks, 3 mo, 6 mo, 1 year, 2 years

  5. Complications

    Time frame: 6 weeks, 3 mo, 6 mo, 1 year, 2 years

07

Study locations

1 site
  • Töölö Hospital Trauma Center, Helsinki University Central Hospital,
    Helsinki, Finland
08

References and documents

Publications

  • Handoll HH, Elliott J, Thillemann TM, Aluko P, Brorson S. Interventions for treating proximal humeral fractures in adults. Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD000434. doi: 10.1002/14651858.CD000434.pub5. PubMed 35727196 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Feb 2024 and a completion of Feb 2024. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2009
First posted
Oct 21, 2009
Start
Nov 2010
Primary completionActual
Feb 22, 2024
CompletionActual
Feb 22, 2024
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00999193
Collaborators
Helsinki University Central Hospital, Finnish Institute for Health and Welfare
Responsible party
Tuomas Lahdeoja (MD, University of Helsinki) — Principal investigator
First posted
Oct 21, 2009
Start date
Nov 2010
Primary completion
Feb 22, 2024
Completion
Feb 22, 2024
Last update
Jan 7, 2025

Study contacts

Tuomas Lähdeoja, MD
principal investigator · University of Helsinki
Mika Paavola, MD, PhD
study director · University of Helsinki
Jarkko Pajarinen, MD, PhD
study director · University of Helsinki
Seppo Koskinen, MD, PhD
study chair · University of Helsinki

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion